2025-03-03T08:48:08-06:00 2024-06-30 871353108 EISNER ADVISORY GROUP LLC 733 THIRD AVENUE NEW YORK NY 100172703 990 2023-07-01 131837442 CANCER RESEARCH INSTITUTE INC CANC 2126887515 29 BROADWAY 4TH FLOOR NEW YORK NY 10006 KATHRYN BEELEY CFO 2126887515 2025-02-26 1 0 TIMOTHY SCHROEDER P01631203 2129498700 2023 2025-03-06 01:10:19Z ALICIA ZHOU PHD 53967271 0 X WWW.CANCERRESEARCH.ORG X 1953 NY SEE ON SCHEDULE OTHE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BYFUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FORALL TYPES OF CANCER. TO ACCOMPLISH THIS, CRI FUNDS LABORATORY,TRANSLATIONAL, AND CLINICAL RESEARCH. 33 33 32 250 0 0 31020217 20143304 0 0 1191003 3783274 84039 38060 32295259 23964638 27521822 22471018 0 0 5330368 5354714 0 0 3445611 5700473 4995164 38552663 32820896 -6257404 -8856258 138008864 133734670 70013010 66904035 67995854 66830635 X SEE SCHEDULE OTHE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER. TO ACCOMPLISH THIS, CRI FUNDS LABORATORY, TRANSLATIONAL, AND CLINICAL RESEARCH. EFFORTS AIMED AT LEARNING HOW TO HARNESS THE POWER OF THE IMMUNE SYSTEM TO DIAGNOSE, TREAT, AND CURE CANCER. CRI ALSO COORDINATES SCIENTIFIC, MEDICAL, AND PATIENT EDUCATION CONFERENCES ON THE SUBJECTS OF IMMUNOLOGY AND IMMUNOTHERAPY, AND DISSEMINATES INFORMATION IN ENGLISH AND SPANISH ABOUT ADVANCES IN TUMOR IMMUNOLOGY TO THE MEDIA, PUBLIC, AND MEDICAL AND SCIENTIFIC COMMUNITIES. 0 0 6250000 6250000 STAR PROGRAM - SEE SCHEDULE OTHE LLOYD J. OLD STAR PROGRAM PROVIDES GRANTS OF $1.25 MILLION OVER 5 YEARS TO MID-CAREER SCIENTISTS. THIS LONG-TERM FUNDING IS NOT TIED TO A SPECIFIC RESEARCH PROJECT, BUT RATHER AIMS TO PROVIDE A DEGREE OF FLEXIBILITY AND FREEDOM FOR INVESTIGATORS TO EXPLORE OUTSIDE-THE-BOX AND DISRUPTIVE AVENUES OF RESEARCH. CANDIDATES SELECTED FOR THIS AWARD ARE EXPECTED TO BE FUTURE "STARS" IN THE FIELD OF CANCER IMMUNOLOGY: SCIENTISTS TAKING RISKS. 6133761 6133761 FELLOWSHIP PROGRAM - SEE SCHEDULE OTHE CRI POSTDOCTORAL FELLOWSHIP PROGRAM INCLUDES THREE TRACKS OF FELLOWSHIPS PROVIDING CAREER DEVELOPMENT, TRAINING, AND DIVERSITY BUILDING IN IMMUNOLOGY AND IMMUNO-INFOMATICS. THE CRI IRVINGTON POSTDOCTORAL FELLOWSHIP, CRI IRVINGTON POSTDOCTORAL FELLOWSHIP TO PROMOTE RACIAL DIVERSITY, AND THE CRI IMMUNO-INFORMATICS FELLOWSHIP EACH SUPPORT YOUNG IMMUNOLOGISTS AND CANCER IMMUNOLOGISTS AT TOP UNIVERSITIES AND RESEARCH CENTERS AROUND THE WORLD. FELLOWS RECEIVE UP TO $243,000 OVER THREE YEARS TO COVER THE COST OF STIPEND, INCLUDING AN INSTITUTIONAL ALLOWANCE TO HELP PAY FOR THE FELLOW'S RESEARCH SUPPLIES, TRAVEL TO SCIENTIFIC MEETINGS, HEALTH INSURANCE, AND/OR CHILDCARE. OF THE MORE THAN 1,620 CRI POSTDOCTORAL FELLOWS FUNDED TO DATE, MANY HAVE SINCE BECOME HEADS OF MAJOR MEDICAL RESEARCH INSTITUTES, ACADEMIC LEADERS IN PRESTIGIOUS UNIVERSITIES, AND ADMIRED MENTORS TO THE NEXT GENERATION OF IMMUNOLOGISTS AND TUMOR IMMUNOLOGISTS. 2979640 2979640 CRI CLINICAL INNOVATOR - SEE SCHEDULE OTHE CRI CLINICAL INNOVATOR SUPPORTS NOVEL CLINICAL STUDIES THAT ADDRESS AREAS OF HIGH UNMET NEED IN CANCER AND SEEKS MECHANISTIC INSIGHTS INTO CLINICAL RESPONSE WITH A GOAL OF PREDICTIVE BIOMARKER DISCOVERY. TO MAXIMIZE THE IMPACT OF EACH CLINICAL TRIAL, CRI WILL ADVISE ON SELECTED STUDIES IN A COORDINATED EFFORT TO OPTIMIZE CLINICAL TRIAL DESIGN AND TRANSLATIONAL STUDIES. FUNDING OF UP TO $1M PER CLINICAL TRIAL IS AWARDED. 11265323 7107617 CRI ANNA-MARIA CLINICAL ACCELERATOR:THE CRI ANNA-MARIA KELLEN CLINICAL ACCELERATOR IS AN ACTIVELY MANAGED VENTURE PHILANTHROPY PROGRAM DESIGNED TO SPEED THE DEVELOPMENT OF PROMISING NEW CANCER IMMUNOTHERAPY COMBINATIONS. THIS MODEL FACILITATES RESEARCH COLLABORATION ACROSS LEADING BIOPHARMA COMPANIES AND THE CRI NETWORK OF IMMUNO-ONCOLOGY EXPERTS. THE PROGRAM INCLUDES PLATFORM CLINICAL TRIALS THAT ARE COLLABORATIVE, INTEGRATIVE, SCIENCE/DATA-DRIVEN, AND HYPOTHESIS-ANSWERING CLINICAL STUDIES. CRI PLANS, IMPLEMENTS, INVESTS IN, AND MANAGES EACH CLINICAL ACCELERATOR CLINICAL TRIAL AND WORKS CLOSELY WITH ACADEMIC RESEARCHER AND INDUSTRY PARTNERS ON SUCH STUDIES. EACH CLINICAL TRIAL AND PHILANTHROPIC INVESTMENT BRINGS A POTENTIAL NEW CANCER TREATMENT CLOSER TO PATIENTS, EMPOWERS ACADEMIC RESEARCHERS TO WORK MORE CLOSELY WITH INDUSTRY, AND CREATES A POTENTIAL RETURN ON INVESTMENT TO BE USED TO SUPPORT FUTURE CLINICAL EFFORTS.CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP):THE CRI CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) SUPPORTS PRE-CLINICAL AND TRANSLATIONAL RESEARCH THAT CAN BE DIRECTLY APPLIED TO OPTIMIZING CANCER IMMUNOTHERAPY IN THE CLINIC. CLIP GRANTS ARE AWARDED TO QUALIFIED SCIENTISTS EXPLORING CLINICALLY RELEVANT QUESTIONS AIMED AT IMPROVING THE EFFECTIVENESS OF CANCER IMMUNOTHERAPIES. CLIP GRANTS PROVIDE UP TO $300,000 OVER TWO YEARS.TECHNOLOGY IMPACT AWARD:THE CRI TECHNOLOGY IMPACT AWARD PROVIDES SEED FUNDING OF UP TO $200,000 TO BE USED OVER 24 MONTHS TO ADDRESS THE GAP BETWEEN TECHNOLOGY DEVELOPMENT AND CLINICAL APPLICATION OF CANCER IMMUNOTHERAPIES.CRI IMPACT GRANTS:CRI IMPACT GRANTS SUPPORT RESEARCH PROJECTS AND PUBLIC EDUCATION AND AWARENESS INITIATIVES WITHIN OR APPLICABLE TO THE FIELDS OF IMMUNOLOGY AND TUMOR IMMUNOLOGY FOR WHICH FUNDS HAVE BEEN SPECIFICALLY RAISED. 11265323 7107617 26628724 1 1 0 0 0 0 0 0 0 1 1 1 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 20 0 1 32 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 33 33 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 NY AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IA IN KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WI WV WY X KATHRYN BEELEY 2126887515 29 BROADWAY 4TH FL NEW YORK NY 10006 PAUL C SHIVERICK CHAIRMEN 5.00 X X 0 0 0 ANDREW K TSAI CHAIRMEN 5.00 X X 0 0 0 DONALD J GOGEL VICE CHAIRMEN 3.00 X X 0 0 0 EDGAR R BERNER VICE CHAIRMEN 3.00 X X 0 0 0 GEOFFREY O COLEY TREASURER 3.00 X X 0 0 0 THOMAS G MENDELL SECRETARY 1.00 X X 0 0 0 TONY ALVAREZ II TRUSTEE 0.50 X 0 0 0 YACOV ARNOPOLIN TRUSTEE 4.00 X 0 0 0 PETER L BLOOM TRUSTEE 4.00 X 0 0 0 BRIAN J BRILLE TRUSTEE 1.00 X 0 0 0 MICHAEL R CRAWFORD TRUSTEE (THRU 4/2024) 1.00 X 0 0 0 W ROBERT DAHL TRUSTEE 1.00 X 0 0 0 MAXWELL DAVID TRUSTEE 0.25 X 0 0 0 GLENN J DESIMONE TRUSTEE (THRU 7/2023) 1.00 X 0 0 0 SEAN P FAHEY TRUSTEE 1.00 X 0 0 0 WILLIAM S GOLDBERG TRUSTEE 0.25 X 0 0 0 OLIVER R GRACE JR TRUSTEE 1.00 X 0 0 0 SANDRA COUDERT GRAHAM TRUSTEE 0.50 X 0 0 0 MICHAEL M KELLEN TRUSTEE 1.00 X 0 0 0 SARAH KIM TRUSTEE 3.00 X 0 0 0 FERN LAZAR TRUSTEE 3.00 X 0 0 0 ALEXANDER P LYNCH TRUSTEE (THRU 7/2023) 1.00 X 0 0 0 SANDRA OZOLA TRUSTEE 0.25 X 0 0 0 MICHAEL J PETRICK TRUSTEE 0.50 X 0 0 0 LIEF D ROSENBLATT TRUSTEE 0.25 X 0 0 0 ANAND SHAH MD TRUSTEE 0.25 X 0 0 0 ADAM SHAPIRO TRUSTEE 0.25 X 0 0 0 FRANK V SICA TRUSTEE 1.00 X 0 0 0 JAMES A STERN TRUSTEE 1.00 X 0 0 0 ROBERT S STOLAR TRUSTEE 1.00 X 0 0 0 MICHAEL B TARGOFF TRUSTEE 1.00 X 0 0 0 DIANE TUFT TRUSTEE 1.00 X 0 0 0 LAUREN S VERONIS TRUSTEE 3.00 X 0 0 0 RONALD G WEINER TRUSTEE 1.00 X 0 0 0 JIM WEISS TRUSTEE 4.00 X 0 0 0 PETER ZHOU TRUSTEE 5.00 X 0 0 0 ALFRED R MASSIDAS TO 22025 CFO & DIRECTOR OF HUMAN RESOURCES 40.00 X 347437 0 90161 JILL O'DONNELL TORMEY TO 824 CEO & DIRECTOR OF SCIENTIFIC AFFAIRS 40.00 X 539137 0 72884 ALICIA ZHOU PHD START 92024 CEO 40.00 X 0 0 0 KATHRYN BEELEY START 22025 CFO 40.00 X 0 0 0 DEANNE T MARBACH DIRECTOR OF MAJOR GIFTS 40.00 X 155690 0 54575 JAY R CAMPBELL MANAGING DIR OF CRI CLINICAL ACCELERATOR 40.00 X 284937 0 83161 LYNNE A RAPINO CHIEF PROGRAM OFFICER 40.00 X 287287 0 84627 RUPINDER KAUR CHIEF INFORMATION OFFICER 40.00 X 247910 0 64351 SHARON S SLADE CHIEF MARKETING OFFICER 40.00 X 273403 0 47760 BRIAN M BREWER CHIEF COMMUNICATIONS OFFICER 40.00 X 148135 0 0 MARLA S LAWSON ASSOC DIR OF CORPORATE RELATIONS 40.00 X 136015 0 52016 QING HUA ZHANG CONTROLLER 40.00 X 147203 0 53996 SAMIK K UPADHAYA ASST DIRECTOR, SCIENTIFIC AFFAIRS 40.00 X 145770 0 54210 SHASELL NEGRON ASSOC DIR, COMMUNITY FUNDRAISING 40.00 X 126437 0 32999 2839361 0 690740 13 0 1 0 SOCIEDAD ADVERTISING 20 STUYVESANT OVAL 7F NEW YORK NY 10009 ADVERTISING SERVICES 200000 1 519098 1451713 18172493 291714 20143304 1102600 1102600 173726 141685 32041 32041 32041 32501311 29820637 2680674 2680674 2680674 40311 1451713 40311 0 MISCELLANEOUS REVENUE 900099 6019 6019 6019 23964638 6019 0 3815315 15486646 15486646 6984372 6984372 2215000 828484 456125 930391 1717003 642217 353575 721211 343426 120868 76241 146317 844042 334699 163250 346093 235243 90144 45340 99759 111231 82594 28637 104490 104490 729119 729119 1157260 393991 478697 284572 216155 42543 173612 748006 328059 37639 382308 453862 193213 102462 158187 153062 71683 17152 64227 973073 973073 41983 16793 9236 15954 52653 52653 MISCELLANEOUS 124027 22686 73783 27558 PRINTING & PUBLICATIONS 103077 16659 125 86293 FILING FEE 27166 18037 9129 32820896 26628724 2746561 3445611 14783358 10427229 1903578 4274302 25188717 20702699 160297 56866 288340 525644 616862 516634 113116 100228 26380379 21955137 66740812 73774051 2450267 1918514 138008864 133734670 667567 1043117 66778175 63844049 2567268 2016869 70013010 66904035 X 44693823 50119968 23302031 16710667 67995854 66830635 138008864 133734670 X -8856258 6518908 1172131 X 0 1 X 1 0 X 35256709 32869987 28733665 31020217 20143304 148023882 35256709 32869987 28733665 31020217 20143304 148023882 24924674 123099208 621444 274125 569941 674270 1134641 3274421 465 7073 37398 44936 1154 25594 9556 54720 6019 97043 151440282 0.81290 0.74960 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME CONSISTS OF CREDIT CARD CASH BACK AND OTHER MISC INCOME - 2019 AMOUNT: $ 1,154. 2020 AMOUNT: $ 25,594. 2021 AMOUNT: $ 9,556. 2022 AMOUNT: $ 54,720. 2023 AMOUNT: $ 6,019. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 10758848 30000 1597795 12386643 9852169 23500 883179 10758848 10885794 19500 -1053125 9852169 8309311 24180 2552303 10885794 8200942 21700 297442 210773 8309311 0.57000 0.29000 0.14000 0 0 99182 67953 42252 517680 448681 57976 100228 PRIVATE EQUITY 36425648 F HEDGE FUNDS 13438177 F FUND OF FUNDS 23910226 F 73774051 LEASE LIABILITY 1985328 SECURITY DEPOST 31541 2016869 X 31293403 6518908 416130 60928 1061918 8057884 23235519 729119 729119 23964638 32507907 416130 416130 32091777 729119 729119 32820896 PART V, LINE 4: THE INSTITUTE'S ENDOWMENT CONSISTS OF FOUR DONOR-RESTRICTED FUNDS AND A BOARD DESIGNATED FUND ESTABLISHED TO SUPPORT FELLOWSHIPS AND OTHER RESEARCH PROGRAMS. PART X, LINE 2: THE INSTITUTE FOLLOWS THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S ("FASB") ACCOUNTING STANDARDS CODIFICATION ("ASC") TOPIC 740, INCOME TAXES, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. FOR THE INSTITUTE, THESE PROVISIONS COULD BE APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME. BECAUSE OF THE INSTITUTE'S GENERAL TAX-EXEMPT STATUS, MANAGEMENT BELIEVES ASC TOPIC 740 HAS NOT HAD, AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON THE INSTITUTE'S FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: CANCELLATION OF GRANTS 1,061,918. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 GRANTS TO RECCIPIENTS 1250000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECCIPIENTS 1376240 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECCIPIENTS 2575132 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECCIPIENTS 1783000 CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 65270465 NORTH AMERICA 0 0 INVESTMENTS 1775635 0 0 0 0 0 0 74030472 0 74030472 EAST ASIA AND THE PACIFIC RESEARCH 1250000 ACH/WIRE 0 NORTH AMERICA RESEARCH 243000 ACH/WIRE 0 NORTH AMERICA RESEARCH 57794 ACH/WIRE 0 NORTH AMERICA RESEARCH 2269338 ACH/WIRE 0 MIDDLE EAST AND NORTH AFRICA RESEARCH 243000 ACH/WIRE 0 MIDDLE EAST AND NORTH AFRICA RESEARCH 90000 ACH/WIRE 0 MIDDLE EAST AND NORTH AFRICA RESEARCH 200000 ACH/WIRE 0 MIDDLE EAST AND NORTH AFRICA RESEARCH 1250000 ACH/WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 196626 ACH/WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 979640 ACH/WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 199974 ACH/WIRE 0 11 1 0 0 0 1 0 PART I, LINE 2: CANCER RESEARCH INSTITUTE INC. REQUIRES GRANT RECIPIENTS TO COMPLY WITH STATED TERMS AND CONDITIONS GOVERNING EACH PROGRAM, INCLUDING THE SUBMISSION OF ANNUAL PROGRESS REPORTS AND, WHERE APPLICABLE, INSTITUTION-GENERATED FINANCIAL REPORTS. DISBURSEMENT OF FUNDS IS CONTINGENT UPON ACCEPTANCE OF THESE TERMS AND TIMELY SUBMISSION OF REPORTS. PART I, LINE 3: AMOUNTS ARE REPORTED ON THE ACCRUAL BASIS. AWARD DINNER 531260 490949 40311 40311 LANDESMAN LADIES NIGHT OUT 305036 305036 3 655728 655728 1492024 1451713 40311 40311 40311 0 1 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501C(3) 67700 0 RESEARCH FOCUSED ULTRASOUND FOUNDATION 1230 CEDARS COURT SUITE 206 CHARLOTTESVILLE VA 22903 205744808 501C(3) 20942 0 RESEARCH THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501C(3) 729000 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131624182 501C(3) 1132000 0 RESEARCH ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE STE 312 BRONX NY 10461 162425500 501C(3) 243000 0 RESEARCH WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501C(3) 243000 0 RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1425 MADISON AVENUE BOX 1630 NEW YORK NY 10029 136171197 501C(3) 243000 0 RESEARCH AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 CHESTNUT STREET PHILADELPHIA PA 19106 236251648 501C(3) 25000 0 RESEARCH EMORY UNIVERSITY 1510 CLIFTON ROAD ATLANTA GA 30322 580566256 501C(3) 243000 0 RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 501C(3) 1015000 0 RESEARCH THE J DAVID GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 123720366 501C(3) 200000 0 RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVE SOUTH BIRMINGHAM AL 35294 163600539 501C(3) 200000 0 RESEARCH UNIVERSITY OF WASHINGTON 1959 NE PACIFIC STREET SEATTLE WA 98195 916001537 501C(3) 160000 0 RESEARCH OHIO STATE UNIVERSITY 205 BRICKER HALL 190 NORTH OVAL MALL COLUMBUS OH 43210 316025986 501C(3) 300000 0 RESEARCH SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE 221 NORTH GRAND BOULEVARD ST LOUIS MO 63103 430654872 501C(3) 299786 0 RESEARCH STANFORD UNIVERSITY 291 CAMPUS DRIVE STANFORD CA 94305 941156365 501C(3) 729000 0 RESEARCH BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501C(3) 1039700 0 RESEARCH UNIVERSITY OF PENNSYLVANIA 3400 CIVIC CENTER BLVD PHILADELPHIA PA 19104 231352685 501C(3) 1793000 0 RESEARCH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES 4 CENTER DRIVE BETHESDA MD 20892 520858115 501C(3) 243000 0 RESEARCH BROAD INSTITUTE OF MIT AND HARVARD 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501C(3) 243000 0 RESEARCH OVERT 430 E 29 ST FLOOR 14 NEW YORK NY 10016 883838475 200000 0 RESEARCH DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02115 042263040 501C(3) 243000 0 RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 513 PARNASSUS AVENUE SAN FRANCISCO CA 94122 946036493 501C(3) 1243000 0 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 041564655 501C(3) 300000 0 RESEARCH UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167352 501C(3) 243000 0 RESEARCH NEW YORK UNIVERSITY MEDICAL CENTER 550 FIRST AVENUE NEW YORK NY 10016 135562309 501C(3) 543000 0 RESEARCH UNIVERSITY OF CHICAGO MEDICAL CENTER 5841 S MARYLAND AVENUE CHICAGO IL 60637 136217139 501C(3) 300000 0 RESEARCH WASHINGTON UNIVERSITY SCHOOL OF MEDICINE 660 S EUCLID AVENUE ST LOUIS MO 63110 430653611 501C(3) 243000 0 RESEARCH COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 701 W 168TH STREET NEW YORK NY 10032 135598093 501C(3) 1250000 0 RESEARCH THE BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501C(3) 6361 0 RESEARCH THE LA JOLLA INSTITUTE FOR IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501C(3) 243000 0 RESEARCH YALE UNIVERSITY SCHOOL OF MEDICINE PO BOX 208055 333 CEDAR STREET NEW HAVEN CT 06520 060646973 501C(3) 1550000 0 RESEARCH PRINCETON UNIVERSITY PRINCETON UNIVERSITY PRINCETON NJ 08544 210634501 501C(3) 243000 0 RESEARCH 32 1 PART I, LINE 2: CANCER RESEARCH INSTITUTE INC. REQUIRES GRANT RECIPIENTS TO COMPLY WITH STATED TERMS AND CONDITIONS GOVERNING EACH PROGRAM, INCLUDING THE SUBMISSION OF ANNUAL PROGRESS REPORTS AND, WHERE APPLICABLE, INSTITUTION-GENERATED FINANCIAL REPORTS. DISBURSEMENT OF FUNDS IS CONTINGENT UPON ACCEPTANCE OF THESE TERMS AND TIMELY SUBMISSION OF REPORTS. X X X 0 0 0 0 0 0 0 0 0 JILL O'DONNELL TORMEY TO 824 CEO & DIRECTOR OF SCIENTIFIC AFFAIRS 539137 0 0 0 0 0 34500 0 38384 0 612021 0 0 0 ALFRED R MASSIDAS TO 22025 CFO & DIRECTOR OF HUMAN RESOURCES 347437 0 0 0 0 0 35500 0 54661 0 437598 0 0 0 LYNNE A RAPINO CHIEF PROGRAM OFFICER 287287 0 0 0 0 0 30000 0 54627 0 371914 0 0 0 JAY R CAMPBELL MANAGING DIR OF CRI CLINICAL ACCELER 284937 0 0 0 0 0 28500 0 54661 0 368098 0 0 0 SHARON S SLADE CHIEF MARKETING OFFICER 273403 0 0 0 0 0 28000 0 19760 0 321163 0 0 0 RUPINDER KAUR CHIEF INFORMATION OFFICER 247910 0 0 0 0 0 26000 0 38351 0 312261 0 0 0 DEANNE T MARBACH DIRECTOR OF MAJOR GIFTS 155690 0 0 0 0 0 16500 0 38075 0 210265 0 0 0 QING HUA ZHANG CONTROLLER 147203 0 0 0 0 0 15800 0 38196 0 201199 0 0 0 SAMIK K UPADHAYA ASST DIRECTOR, SCIENTIFIC AFFAIRS 145770 0 0 0 0 0 16000 0 38210 0 199980 0 0 0 MARLA S LAWSON ASSOC DIR OF CORPORATE RELATIONS 136015 0 0 0 0 0 13850 0 38166 0 188031 0 0 0 SHASELL NEGRON ASSOC DIR, COMMUNITY FUNDRAISING 126437 0 0 0 0 0 13500 0 19499 0 159436 0 0 0 X 34 291714 FAIR MARKET VALUE 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE CEO AND THE CFO WORK WITH THE AUDIT FIRM TO PREPARE THE TAX RETURNS. A DRAFT COPY IS CIRCULATED TO THE ENTIRE BOARD FOR REVIEW AND COMMENTS, AFTER WHICH IT IS SIGNED AND FILED WITH RELEVANT AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD AND THE ENTIRE STAFF ARE GIVEN THE CONFLICT OF INTEREST DOCUMENT. THEY ARE ASKED TO ANSWER ALL QUESTIONS AND MAKE THE NECESSARY DECLARATIONS AND THEN SIGN THE DOCUMENT ON AN ANNUAL BASIS. FORM 990, PART VI, SECTION B, LINE 15 THE PROCESS FOR DETERMINING COMPENSATION OF THE CEO IS DETERMINED BY USING COMPARABLE DATA AND IS REVIEWED BY THE BOARD OF TRUSTEES CO-CHAIRMEN. FORM 990, PART VI, SECTION C, LINE 19 AT LEAST THE THREE MOST RECENT YEARS OF FINANCIAL INFORMATION ARE POSTED ON CRI'S WEBSITE. THE GENERAL PUBLIC CAN ALSO REQUEST A COPY TO BE SENT TO THEM, AS WELL AS VIEW THEM AT OUR OFFICES AT 29 BROADWAY, 4TH FLOOR NEW YORK, NY 10006. GOVERNING DOCUMENTS ARE ONLY DISTRIBUTED INTERNALLY TO MANAGEMENT AND THE BOARD OF TRUSTEES. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF PERPETUAL TRUST 49,285. CANCELLATION OF GRANTS 1,061,918. GRANT REFUNDS 60,928.